| No. | Case | Principal Investigator |
| 1 | To preliminarily confirm the correlation with the major metabolites in Neurodegenerative disorders and highly Neurodegenerative disorders-related mitochondrial genes | Huang, Hui-Yu |
| 2 | Investigation the malignant role of Histamine Receptor H1 (HRH1) in head and neck squamous cell carcinoma and the potential of targeting HRH1 as a therapeutic option | Chien, Ming-Hsien |
| 3 | Development of Different Cancers Biomarkers for Precision Medicine with Big Data Analyses_Targeted drug development | Jer-Wei Chang |
| 4 | Integration of protein, genetic, and epigenetic biomarkers for early detection of ovarian cancer in plasma and urine samples | Kuo-Min, Su |
| 5 | Beneath the Waves: Investigating the Anti-Ovarian Cancer Potential of Sponge-Derived Compounds | Tsui-Chin Huang |
| 6 | Exploration and validation of microRNAs as predictive biomarkers for coronary artery disease (CAD) | Nianhan Ma |
| 7 | Development of Different Cancers Biomarkers for Precision Medicine with Big Data Analyses_Neoantigen development | Jer-Wei Chang |
| 8 | Development of Different Cancers Biomarkers for Precision Medicine with Big Data Analyses_Drug response prediction model development. | Jer-Wei Chang |
| 9 | Investigating expression of a novel cancer marker and activity of tumor-associated proteases in solid tumors | Liu Yun-Ru |
| 10 | Targeting CEACAM6 for colorectal cancer theranostics | MinHsuan Yen |
| 11 | Development of a polygenic risk assessment model for breast cancer patients in Taiwan | Liu Yun-Ru |
| 12 | The feasibility assessment of using exosomal proteins and microRNAs as indicators for recurrent monitoring in triple-negative breast cancer. | Liu Yun-Ru |
| 13 | Investigating the Role of PLCB4 in Colorectal Cancer Metastasis via the JAK/STAT3 Signaling Pathway: Molecular Insights and Clinical Implications | Yu-Jia Chang |
| 14 | Using comprehensive cancer genetic testing and national biobank consortium of Taiwan database information to explore the genetic variation expression, clinical manifestations and treatment results of Taiwan's six advanced cancer patients | Ming-Fang Wu |
